Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors

MLA

Julie M. Shabto, et al. “Novel Risk Group Stratification for Metastatic Urothelial Cancer Patients Treated with Immune Checkpoint Inhibitors.” Cancer Medicine, vol. 9, no. 8, Apr. 2020, pp. 2752–60. EBSCOhost, https://doi.org/10.1002/cam4.2932.

APA

Julie M. Shabto, Dylan J. Martini, Yuan Liu, Deepak Ravindranathan, Jacqueline Brown, Emilie E. Hitron, Greta A. Russler, Sarah Caulfield, Haydn Kissick, Mehrdad Alemozaffar, Kenneth Ogan, Wayne B. Harris, Viraj A. Master, Omer Kucuk, Bradley C. Carthon, & Mehmet A. Bilen. (2020). Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. Cancer Medicine, 9(8), 2752–2760. https://doi.org/10.1002/cam4.2932

Chicago

Julie M. Shabto, Dylan J. Martini, Yuan Liu, Deepak Ravindranathan, Jacqueline Brown, Emilie E. Hitron, Greta A. Russler, et al. 2020. “Novel Risk Group Stratification for Metastatic Urothelial Cancer Patients Treated with Immune Checkpoint Inhibitors.” Cancer Medicine 9 (8): 2752–60. doi:10.1002/cam4.2932.